The Conundrum of Antifungal Resistance: Emergence of Nakaseomyces Glabratus (Candida Glabrata) in Europe with Global Implications
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Gupta A, Wang T J Eur Acad Dermatol Venereol. 2025; 39(2):255-256.
PMID: 39854082 PMC: 11761013. DOI: 10.1111/jdv.20473.
References
1.
Lee J, Cohen R, Khan R, Burry J, Casas E, Chung H
. Paving the way for affordable and equitable liposomal amphotericin B access worldwide. Lancet Glob Health. 2024; 12(9):e1552-e1559.
PMC: 11345448.
DOI: 10.1016/S2214-109X(24)00225-0.
View
2.
Kwizera R, Abdolrasouli A, Garcia-Effron G, Denning D
. Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings. Lancet Infect Dis. 2024; 24(12):e782-e793.
DOI: 10.1016/S1473-3099(24)00429-8.
View
3.
Lockhart S, Chowdhary A, Gold J
. The rapid emergence of antifungal-resistant human-pathogenic fungi. Nat Rev Microbiol. 2023; 21(12):818-832.
PMC: 10859884.
DOI: 10.1038/s41579-023-00960-9.
View
4.
Rodriguez-Cerdeira C, Pinto-Almazan R, Saunte D, Hay R, Szepietowsk J, Szepietowski J
. Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review. J Eur Acad Dermatol Venereol. 2024; 39(2):377-388.
PMC: 11760688.
DOI: 10.1111/jdv.20273.
View
5.
Gupta A, Wang T
. The conundrum of antifungal resistance: Emergence of Nakaseomyces glabratus (Candida glabrata) in Europe with global implications. J Eur Acad Dermatol Venereol. 2025; 39(2):255-256.
PMC: 11761013.
DOI: 10.1111/jdv.20473.
View